The Development and SAR of Selective Sigma-2 Receptor Ligands for the Diagnosis of Cancer Mark Ashford University of Wollongong
Total Page:16
File Type:pdf, Size:1020Kb
University of Wollongong Research Online University of Wollongong Thesis Collection University of Wollongong Thesis Collections 2010 The development and SAR of selective sigma-2 receptor ligands for the diagnosis of cancer Mark Ashford University of Wollongong Recommended Citation Ashford, Mark, The development and SAR of selective sigma-2 receptor ligands for the diagnosis of cancer, Doctor of Philosophy thesis, School of Chemistry, University of Wollongong, 2010. http://ro.uow.edu.au/theses/3634 Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] The Development and SAR of Selective Sigma-2 Receptor Ligands for the Diagnosis of Cancer Mark E. Ashford B. Med. Chem. Hons (Adv) A thesis submitted in fulfilment of the requirements for the award of the degree Doctor of Philosophy From University of Wollongong School of Chemistry August 2010 Declaration I, Mark Edward Ashford, declare that this thesis, submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the School of Chemistry, Faculty of Science, University of Wollongong, is wholly my own work unless otherwise referenced or acknowledged. The document has not been submitted for qualifications at any other academic institution. Mark E. Ashford 2010 Mark Ashford, PhD Thesis 2010 ii Table of Contents Declaration.......................................................................................................................ii List of Figures.................................................................................................................vi List of Schemes .............................................................................................................viii List of Tables ...................................................................................................................x Abbreviations .................................................................................................................xi Publications and Presentations ...................................................................................xiv Acknowledgements........................................................................................................xv Abstract.........................................................................................................................xvi 1. Introduction.............................................................................................................1 1.1. Sigma Receptors................................................................................................1 1.2. Sigma Receptor Subtypes..................................................................................2 1.2.1. Sigma-1 Receptor..............................................................................................2 1.2.2. Sigma-2 Receptor..............................................................................................3 1.3. Synthetic Sigma-2 Ligands ...............................................................................3 1.4. Sigma-2 Receptor Function...............................................................................4 1.4.1. Apoptosis ..........................................................................................................4 1.5. The role of Sigma-2 Receptors in Disease........................................................5 1.5.1. Cancer ...............................................................................................................5 1.6. Classes of Sigma-2 Ligands..............................................................................6 1.6.1. Spiro and Phenylpiperidines..............................................................................7 1.6.2. Azabicyclic Ligands..........................................................................................8 1.6.3. Benzamide Analogues.......................................................................................9 1.7. Radiopharmaceutical Chemistry.....................................................................11 1.7.1. Radionuclides..................................................................................................11 1.7.2. Radiopharmaceuticals .....................................................................................12 1.7.3. Imaging Modalities .........................................................................................14 1.8. Radiolabelled Sigma-2 Ligands......................................................................15 1.8.1. 123 I Labelled Ligands.......................................................................................16 1.9. Project Aims....................................................................................................17 2. Synthesis of Region 3 Aromatic Derivatives.......................................................19 2.1. Rationale for targeted compounds...................................................................19 2.2. SAR of Region 3.............................................................................................19 2.3. Synthesis of the key intermediate 4-((3,4-dihydro-6,7-dimethoxyisoquinolin- 2(1 H)-yl)methyl)piperidine-1-yl)amine [34] ..................................................21 2.4. Amine coupling reactions and preparation of [36] ..........................................23 2.5. Synthesis of the 4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1 H)- yl)methyl)piperidine-1-yl) amides with region 3 modification ......................24 2.5.1. Non-halogenated amides.................................................................................24 Mark Ashford, PhD Thesis 2010 iii 2.6. Halogenated amides........................................................................................26 2.6.1. Synthesis of 5-iodobenzofuran-2-carboxylic acid [44] ...................................29 2.7. Synthesis of target halogenated amides ..........................................................33 2.8. In vitro binding of amide derivatives..............................................................35 2.9. Lipophilicity Estimates ...................................................................................39 2.10. Attempted further modification to Region 3...................................................39 2.11. Conclusion ......................................................................................................40 3. Synthesis of Region 2 Carbon Spacer Derivatives.............................................42 3.1. Modification of Region 2................................................................................42 3.2. General Synthetic Strategy..............................................................................43 3.3. Synthesis of flexible benzamide intermediates...............................................44 3.3.1. Synthesis of target amines [70] -[72] ...............................................................44 3.4. Synthesis of flexible spacer target amides [73] -[78] .......................................46 3.5. In vitro studies and log P.................................................................................50 3.6. Amides with semi-rigid spacers......................................................................52 3.6.1. Synthesis of key amines [90] and [91] ............................................................53 3.6.2. Synthesis of target compounds [92] -[95] with a ethyl- or propylpiperidine spacer.....................................................................................................…….55 3.7. Synthesis of propylpiperazine target compound [102] ....................................56 3.7.1. Method 1: Synthesis of amine intermediate [101] via the Boc protected piperazine [99] ................................................................................................57 3.7.2. Method 2: Synthesis of piperazine [101] via the benzyl protected piperazine [100] ..............................................................................................………….60 3.8. Synthesis of target amide [104] .......................................................................63 3.9. In vitro studies and log P.................................................................................64 3.10. Conclusions and future directions...................................................................65 4. Synthesis of Region 3 Isoquinoline Derivatives..................................................67 4.1. Rationale .........................................................................................................67 4.2. Isoquinoline Synthesis ....................................................................................67 4.3. Formation of isoquinoline intermediates ........................................................73 4.3.1. Synthesis of conformationally flexible intermediates using isoquinolines [105] , [108] and [115a] . .................................................................................73 4.3.2. Synthesis of conformationally semi-restricted intermediates using isoquinolines [108] and [115a] .......................................................................74 4.4. Synthesis and in vitro evaluation of amides with region 3 modification........75 4.4.1. Synthesis of target flexible spacer amides [134] -[136] and semi-rigid amides [137] -[138] .....................................................................................................75